Department of Justice

Small Doses: March 2018 Edition
Small Doses: March 2018 EditionEasy-to-swallow news and studies for the busy pharmacist.
Kmart Settles False Claims/Overbilling Case for $32.3 MillionThe chain allegedly failed to disclose discounted prescription drugs.
Drug Maker Ordered to Shut DownAfter repeated infractions, a company is forced to shutter its doors.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.
Payer mega mergers in question: Industry expert weighs inMichael Abrams of Numerof and Associates healthcare consulting firm discusses how the DOJ’s actions to block the Anthem-Cigna and Aetna-Humana mergers could affect the industry.
Pfizer makes huge multimillion-dollar Medicaid settlementIn one of the biggest drug pricing settlements in history, Pfizer is paying $784.6 million to settle claims alleging that the practices of its Wyeth subsidiary relating to the calculation of Medicaid rebates for Protonix (pantoprazole sodium) violated the Federal Civil False Claims Act and other laws.
Union of American Eye Care Providers initiates anti-trust complaint against vision care plansRepresentatives of the Union of America Eye Care Providers recently met with the Department of Justice’s Healthcare Anti-Trust Division to argue the organization’s position that the vision care plan industry’s policies have an anti-competitive affect on the vision care industry.
Emergency contraceptive’s curious path to OTC
Emergency contraceptive’s curious path to OTCIn June 2013, the Department of Justice under the Obama administration announced an end to its lawsuits regarding age restrictions on “Plan B One-Step” (levonorgestrel), the morning-after pill. The DOJ decided not to appeal the ruling by Judge Edward Korman of the District Court of Eastern New York.